Neil A. O’Brien

2.3k total citations
55 papers, 1.6k citations indexed

About

Neil A. O’Brien is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Neil A. O’Brien has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 20 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Neil A. O’Brien's work include HER2/EGFR in Cancer Research (22 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Advanced Breast Cancer Therapies (11 papers). Neil A. O’Brien is often cited by papers focused on HER2/EGFR in Cancer Research (22 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Advanced Breast Cancer Therapies (11 papers). Neil A. O’Brien collaborates with scholars based in United States, Ireland and Switzerland. Neil A. O’Brien's co-authors include Dennis J. Slamon, Norma O’Donovan, John Crown, Michael J. Duffy, Richard S. Finn, Brigid C. Browne, Sara A. Hurvitz, Dylan Conklin, Charles Ginther and Yufang Hu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Neil A. O’Brien

53 papers receiving 1.6k citations

Peers

Neil A. O’Brien
José Jiménez Spain
Brent N. Rexer United States
Edward Rosfjord United States
Ariella B. Hanker United States
Joan T. Garrett United States
Karin Beelen Netherlands
Maria G. Olivares United States
María G. Kuba United States
Yasir H. Ibrahim United States
Olga Rodríguez Spain
José Jiménez Spain
Neil A. O’Brien
Citations per year, relative to Neil A. O’Brien Neil A. O’Brien (= 1×) peers José Jiménez

Countries citing papers authored by Neil A. O’Brien

Since Specialization
Citations

This map shows the geographic impact of Neil A. O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil A. O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil A. O’Brien more than expected).

Fields of papers citing papers by Neil A. O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil A. O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil A. O’Brien. The network helps show where Neil A. O’Brien may publish in the future.

Co-authorship network of co-authors of Neil A. O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Neil A. O’Brien. A scholar is included among the top collaborators of Neil A. O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil A. O’Brien. Neil A. O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Espinoza, Andres F., Rohit Srivastava, Roma H. Patel, et al.. (2025). Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Scientific Reports. 16(1). 1410–1410.
2.
O’Brien, Neil A., Martina S.J. McDermott, KeWei Gong, et al.. (2023). Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Molecular Cancer Therapeutics. 22(12). 1365–1375. 5 indexed citations
3.
McDermott, Martina S.J., Neil A. O’Brien, KeWei Gong, et al.. (2023). Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clinical Cancer Research. 29(11). 2131–2143. 25 indexed citations
4.
Wainberg, Zev A., Arun S. Singh, Gottfried E. Konecny, et al.. (2022). Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clinical Cancer Research. 29(1). 40–49. 3 indexed citations
5.
6.
Zoeller, Jason J., Krishan Taneja, Benjamin Y. Tan, et al.. (2019). Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Molecular Cancer Therapeutics. 18(6). 1115–1126. 25 indexed citations
7.
Κουτσιούμπα, Μαρίνα, Hsiao‐Wang Chen, Neil A. O’Brien, et al.. (2018). MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Molecular Cancer Therapeutics. 17(7). 1430–1440. 19 indexed citations
8.
Canonici, Alexandra, Neil T. Conlon, Denis M. Collins, et al.. (2018). The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investigational New Drugs. 36(4). 581–589. 19 indexed citations
9.
O’Brien, Neil A., Dylan Conklin, Richard P. Beckmann, et al.. (2018). Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(5). 897–907. 80 indexed citations
10.
Canonici, Alexandra, Neil T. Conlon, Kasper Pedersen, et al.. (2018). HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Investigational New Drugs. 37(3). 441–451. 21 indexed citations
11.
McDermott, Martina S.J., Alexandra Canonici, Brigid C. Browne, et al.. (2017). Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. International Journal of Oncology. 50(6). 2221–2228. 24 indexed citations
12.
Guibourdenche, M, Brigid C. Browne, Lorraine O’Driscoll, et al.. (2017). Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model. Annals of Oncology. 28. v4–v4. 1 indexed citations
13.
O’Brien, Neil A., Tong Luo, Erika von Euw, et al.. (2014). Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research. 20(13). 3507–3520. 93 indexed citations
14.
Russo, Rosalía I. Cordo, Wendy Béguelin, María C. Díaz Flaqué, et al.. (2014). Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene. 34(26). 3413–3428. 42 indexed citations
15.
Liu, Bin, Yonghui Yang, Cary Hsu, et al.. (2014). PIAS1 Regulates Breast Tumorigenesis through Selective Epigenetic Gene Silencing. PLoS ONE. 9(2). e89464–e89464. 33 indexed citations
16.
Wainberg, Zev A., Adrian Anghel, Amrita Desai, et al.. (2013). Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer. Molecular Cancer Therapeutics. 12(4). 509–519. 58 indexed citations
17.
Hurvitz, Sara A., Yufang Hu, Neil A. O’Brien, & Richard S. Finn. (2012). Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews. 39(3). 219–229. 113 indexed citations
18.
Browne, Brigid C., Alex J. Eustace, Susan Kennedy, et al.. (2012). Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Research and Treatment. 136(3). 717–727. 32 indexed citations
19.
O’Brien, Neil A., Brigid C. Browne, Lucy Chow, et al.. (2010). Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib. Molecular Cancer Therapeutics. 9(6). 1489–1502. 249 indexed citations
20.
Browne, Brigid C., Neil A. O’Brien, Michael J. Duffy, John Crown, & Norma O’Donovan. (2009). HER-2 Signaling and Inhibition in Breast Cancer. Current Cancer Drug Targets. 9(3). 419–438. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Jiménez Breakdown of academic impact, for papers by Brent N. Rexer Breakdown of academic impact, for papers by Edward Rosfjord Breakdown of academic impact, for papers by Ariella B. Hanker Breakdown of academic impact, for papers by Joan T. Garrett Breakdown of academic impact, for papers by Karin Beelen Breakdown of academic impact, for papers by Maria G. Olivares Breakdown of academic impact, for papers by María G. Kuba Breakdown of academic impact, for papers by Yasir H. Ibrahim Breakdown of academic impact, for papers by Olga Rodríguez
Rankless by CCL
2026